Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Date:11/9/2007

ng innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, including summary statements relating to the interim or preliminary results of clinical trials involving Amrubicin. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. Preliminary results may not be confirmed upon final analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Amrubicin may be discovered upon further analysis of clinical trial data and upon review and analysis of additional clinical trial data from this or other clinical trials. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Pharmion also disclaims any duty to comment upon or correct information that may be contained in reports published by the inves
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
7. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
8. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
9. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...   Oriel STAT A MATRIX announces ... most critical compliance and performance issues in the ... are experiencing an industry-transforming level of demand and ... global supply chains are negatively impacting product quality ... regulators are increasing compliance requirements, scrutiny, and enforcement. ...
(Date:3/2/2015)... 2, 2015  Akron Children,s Hospital has been designated ... American College of Radiology (ACR), making it the first ... second children,s hospital in the United States ... "Earning recognition from the ACR as a DICOE provides ... level compared with national benchmarks," says Dr. Michael ...
(Date:3/2/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... proven cancer therapies in new orphan drug indications, ... Allowance from the U.S. Patent and Trademark Office ... Compositions and methods to improve the therapeutic benefit ...
Breaking Medicine Technology:Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 2Oriel STAT A MATRIX Announces New Professional Certification Programs for Medical Device Regulatory and Quality Assurance Professionals 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 2DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 3DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083 4
... NEW YORK, March 21, 2011 The Alzheimer,s Drug ... grant of $170,750 to ADispell Inc. to develop small ... loss that occurs with Alzheimer,s Disease. ... licensed technology from Cornell University to develop neuroprotective drug ...
... LLC , ( www.curemark.com ), a drug research and development ... the company has completed its targeted enrollment of Phase III ... Curemark has reached its targeted enrollment for the study ... CM-AT Phase III trial at 18 sites across the country. ...
Cached Medicine Technology:Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease 2Curemark Completes Enrollment of Phase III Autism Trials 2
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 ... Administration (FDA) warned against the use of power ... and fibroid removal surgeries, insurer UnitedHealthCare is poised ... use of those devices. In a notification sent ... beginning in April, it would require pre-authorization for ...
(Date:3/2/2015)... New York (PRWEB) March 02, 2015 ... of Idoll Magazine, a medium for the model agency ... can find, and buy Mango, Passion Fruit, Pink Grapefruit, ... March 3rd, 2015, after 1pm. , At a cost ... has recently came under fire by announcing the brands ...
(Date:3/2/2015)... Gummy smile reduction expert, Dr. Alex ... involve one or several procedures to reduce the appearance of ... a more even gum line. Dr. Farnoosh is the creator ... can permanently lighten discolored or naturally dark gums. , ... personalized treatment plan to address a patient’s specific needs based ...
(Date:3/2/2015)... Minnetonka, MN (PRWEB) March 02, 2015 ... accredited temperature calibration for Secondary Standard Platinum ... (RTDs) in 5 business days or less . ... is NVLAP ® Accredited (Lab Code 200706-0), ... NIST traceability. Temperature range is -196°C to ...
(Date:3/2/2015)... Over the last five years the ultrasound market ... expand their geographic presence and achieve economies of scale. ... billion by 2019 at CAGR of 5.1% from 2014 ... Canada and a major part of Europe are mature ... Asia-Pacific including China and India, Latin America and the ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 2Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 3Health News:Power Morcellator Lawyers at Bernstein Liebhard LLP Comment on Insurers’ Decision to Restrict Most Common Form of Hysterectomies 4Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3
... a company developing breakthrough molecular imaging agents ... announced today that the United States Patent ... 7,438,891, covering methods of imaging cardiovascular plaque ... patent, exclusively licensed from the Massachusetts General ...
... Increased 2% and Increased 1% Excluding the Impact of Foreign ... Decreased 7% and Decreased 1% Excluding the Impact of Foreign ... Increase Led by Growth in Excess of 10% for Prevnar, ... Jan. 26 Wyeth (NYSE: WYE ) today ...
... Saint Joseph,s Health System announced,that it has launched ... a,non-profit training center for robotic surgical teams from around ... Thoracic Surgeons (STS) annual,meeting in San Francisco. , ... to patients from robotic-assisted,surgery since we began our program ...
... To Stay Happy and Healthy This WinterSAN JOSE, Calif., ... avoiding the "winter blues" is to set small goals, ... and exercising, for a well-rounded approach to life. This ... Day of the Year," January 26, 2009, designated by ...
... Jan. 26 Concentric Medical, Inc., the global leader ... today announced that the company,s Merci Retrieval System(TM) has ... in August 2004. The Merci Retrieval System is ... to remove blood clots from patients suffering an ischemic ...
... Internal Manufacturing Scale-Up Underway to Support Increased Product ... (OTC Bulletin Board: BLFS), a leading developer and ... media products for cells, tissues, and organs, today ... full year 2008 and also the receipt of ...
Cached Medicine News:Health News:FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 2Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 3Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 4Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 5Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 6Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 7Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 8Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 9Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 10Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 11Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 12Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 13Health News:Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter 14Health News:Saint Joseph's Launches International College of Robotic Surgery 2Health News:Natural Solutions for the Most Depressing Day of the Year 2Health News:Natural Solutions for the Most Depressing Day of the Year 3Health News:Natural Solutions for the Most Depressing Day of the Year 4Health News:Natural Solutions for the Most Depressing Day of the Year 5Health News:Concentric Medical Reaches Important Stroke Milestone 2Health News:Concentric Medical Reaches Important Stroke Milestone 3Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 2Health News:BioLife Solutions Announces Record Revenue and Receipt of Funding 3
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... cost-effective method of providing patient warming while ... warming tube is ideal for use in ... Radiology. The CSZ Warming Tube is the ... it may be used in almost any ...
... Our patient warming system consists of ... a range of blankets for use ... all clinical applications. Blankets are available ... adult and paediatric sizes and a ...
... is the automated benchtop solution for nucleic ... extensive integrated features and a sample throughput ... the system meets the demanding nucleic acid ... to medium sample throughput., ,The high-quality nucleic ...
Medicine Products: